Compile Data Set for Download or QSAR
Report error Found 133 Enz. Inhib. hit(s) with all data for entry = 10667
TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558587(N-(4-(3,8-diazabicyclo[3.2.1]octan-3-yl) phenyl)-6...)
Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558572((R)-6-(2-chloro-3,5-dimethoxyphe- nyl)-N-(4-(hexah...)
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558594((R)-6-(2,6-dichloro-3,5-dimethoxyphe- nyl)-N-(4-(h...)
Affinity DataIC50: 0.600nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558589(6-(2-chloro-3,5-dimethoxyphenyl)-N- (1,2,3,4-tetra...)
Affinity DataIC50: 0.600nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558595(6-(2,6-dichloro-3,5-dimethoxyphenyl)- N-(4-(4-morp...)
Affinity DataIC50: 0.700nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558592((4-((6-(2-chloro-3,5-dimethoxyphenyl)- [1,2,4]tria...)
Affinity DataIC50: 0.700nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558580((S)-6-(2-chloro-3,5-dimethoxyphe- nyl)-N-(4-(hexah...)
Affinity DataIC50: 0.700nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558558(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(4-ethylpip...)
Affinity DataIC50: 0.740nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558583(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(morpholino...)
Affinity DataIC50: 0.800nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558576(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(4-morpholi...)
Affinity DataIC50: 0.800nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558590(6-(2-chloro-3,5-dimethoxyphenyl)-N- (4-((3S,5R)-3,...)
Affinity DataIC50: 0.800nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558572((R)-6-(2-chloro-3,5-dimethoxyphe- nyl)-N-(4-(hexah...)
Affinity DataIC50: 0.800nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558594((R)-6-(2,6-dichloro-3,5-dimethoxyphe- nyl)-N-(4-(h...)
Affinity DataIC50: 0.800nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558596(US11365196, Compound 67)
Affinity DataIC50: 0.860nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558560(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(4-isopropy...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558563(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(4-(dimethy...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558581((R)-6-(2-chloro-3,5-dimethoxyphe- nyl)-N-(4-(hexah...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558612(US11365196, Compound 104)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558562(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(4-(oxetan-...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558614(US11365196, Compound 106)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558564(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(4-methylpi...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558615(US11365196, Compound 107)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558597(6-(5-chloro-2-methyl-1H-indol-6-yl)-N-(4-(4- ethyl...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558571(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(8-methyl-3...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558570(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(N-(2-dimet...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558586(6-(2-chloro-3,5-dimethoxyphenyl)-N- (4-((3S,5R)-3,...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558573((S)-6-(2-chloro-3,5-dimethoxyphe- nyl)-N-(4-(hexah...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558575(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(2-(pyrroli...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558574(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(3,3,4-trim...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558588(6-(2-chloro-3,5-dimethoxyphenyl)-N- (3-methyl-4-(p...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558601(N-(4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)- yl)phe...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558607(US11365196, Compound 100)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558593(US11365196, Compound 61)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558578(2-(4-(4-((6-(2-chloro-3,5-dime- thoxyphenyl)-[1,2,...)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558610(US11365196, Compound 102-2)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558584(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-((4-methylp...)
Affinity DataIC50: 1.20nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558576(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(4-morpholi...)
Affinity DataIC50: 1.20nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558623(US11365196, Compound 115)
Affinity DataIC50: 1.30nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558580((S)-6-(2-chloro-3,5-dimethoxyphe- nyl)-N-(4-(hexah...)
Affinity DataIC50: 1.30nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558589(6-(2-chloro-3,5-dimethoxyphenyl)-N- (1,2,3,4-tetra...)
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558599(6-(5-chloro-2-methyl-1H-benzo[d]imidazol-6- yl)-N-...)
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558580((S)-6-(2-chloro-3,5-dimethoxyphe- nyl)-N-(4-(hexah...)
Affinity DataIC50: 1.60nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558576(6-(2-chloro-3,5-dimethoxyphenyl)- N-(4-(4-morpholi...)
Affinity DataIC50: 1.70nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558572((R)-6-(2-chloro-3,5-dimethoxyphe- nyl)-N-(4-(hexah...)
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558609(US11365196, Compound 102)
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558598(6-(5-chloro-2-methyl-1H-benzo[d]imidazol-6- yl)-N-...)
Affinity DataIC50: 1.90nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558600(6-(5-chloro-2-methyl-1H-benzo[d]imidazol-6- yl)-N-...)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558572((R)-6-(2-chloro-3,5-dimethoxyphe- nyl)-N-(4-(hexah...)
Affinity DataIC50: 2.20nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetFibroblast growth factor receptor 1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558619(US11365196, Compound 111)
Affinity DataIC50: 2.20nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM558587(N-(4-(3,8-diazabicyclo[3.2.1]octan-3-yl) phenyl)-6...)
Affinity DataIC50: 2.40nMAssay Description:The inhibitory activity of some compounds of the present disclosure against FGFR1, FGFR2, FGFR3, FGFR4, KDR was tested by mobility shift assay (conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

Displayed 1 to 50 (of 133 total ) | Next | Last >>
Jump to: